论文部分内容阅读
目的 :观察干扰素a - 2b远期疗效。方法 :将在我科住院的曾用干扰素a - 2b抗病毒治疗和未抗病毒治疗的复发慢性乙肝患者 ,在相同治疗条件下 ,观察其血清总胆红素 (SB)、谷丙转氨酶 (ALT)、血清白蛋白(ALB)的变化情况及相应的住院时间和住院费用。结果 :与未抗病毒治疗的复发慢性乙肝患者相比 ,干扰素a- 2b治疗后的慢性乙肝患者再次出现肝功能损害时 ,其治疗有效率明显提高 (P <0 .0 5 ) ,血清总胆红素 (SB)下降速率明显增快 (P <0 .0 5 ) ,平均住院时间及治疗费用明显减少 (P <0 .0 5 )。结论 :干扰素a - 2b可能改善慢性乙肝的预后。
Objective: To observe the long-term efficacy of interferon a-2b. Methods: The patients with recurrent chronic hepatitis B who were treated with interferon a - 2b antiviral therapy and without antiviral therapy who were hospitalized in our department were enrolled in this study. Their serum levels of total bilirubin (SB), alanine aminotransferase ALT), serum albumin (ALB) changes and the corresponding hospitalization and hospitalization costs. Results: Compared with patients with recurrent chronic hepatitis B who did not have antiviral therapy, the effective rate of treatment was significantly higher in patients with chronic hepatitis B after interferon a-2b treatment (P <0. 05) The declining rate of bilirubin (SB) was significantly increased (P <0.05), and the average length of hospital stay and treatment costs were significantly decreased (P <0.05). Conclusion: Interferon a - 2b may improve the prognosis of chronic.